Tryp Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TRYPF research report →
Price Chart
About the company
Tryp Therapeutics Inc. is a biopharmaceutical company dedicated to identifying and advancing novel therapeutic compounds for medical conditions characterized by significant unmet needs. Its flagship development initiative, known as PFN, focuses on addressing neuropsychiatric disorders by utilizing precisely formulated synthetic psilocybin.
- CEO
- Jason Carroll
- IPO
- 2021
- HQ
- Kelowna, BC, CA
Get TickerSpark's AI analysis on TRYPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $5.42M
- P/E
- -1.10
- PEG
- -0.02
- P/S
- 0.00
- P/B
- -1.54
- EV/EBITDA
- -1.60
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 402.50%
- ROIC
- 356.62%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-4,701,745
- Net Income
- $-5,267,073+29.7%
- EPS
- $-0.05+43.1%
- OCF Growth
- +37.7%
- FCF Growth
- +39.0%
- 52W High
- $0.09
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.04
- Beta
- -1.28
- RSI (14)
- 73
- Avg Volume
- 49.24K
No earnings-call transcripts are available for TRYPF yet.
- Free Float
- 159.7%
- Shares Outstanding
- 96.42M
- Float Shares
- 154.01M
Our TRYPF coverage
Recent articles, reports, and earnings notes.
No research on TRYPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TRYPF report →Tryp Therapeutics Files Amended Financial Statements for the Six Months Ended February 29, 2024
newsfilecorp.com · May 17
Tryp Therapeutics and Exopharm Limited Announce Completion of Plan of Arrangement
accesswire.com · May 1
CSE Bulletin: Delist - Tryp Therapeutics Inc. (TRYP)
newsfilecorp.com · Apr 24
Tryp Therapeutics Provides Update on Plan of Arrangement With Exopharm Limited and Announces Voluntary Trading Halt
accesswire.com · Apr 24
Tryp Therapeutics Announces 99.92% Votes Cast by Shareholders in Favor of Arrangement Agreement at Annual General and Special Meeting of Securityholders, and Receipt of Final Order
accesswire.com · Mar 12
CSE Bulletin: Reinstatement - Tryp Therapeutics Inc. (TRYP)
newsfilecorp.com · Mar 5
Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting
accesswire.com · Feb 8
Tryp Therapeutics and Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
accesswire.com · Jan 26
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.